$EYPT (EYEPOINT) — 8-K: EyePoint plans FDA submission for DURAVYU in wet AMD in H1 2027

EyePoint presented expanded LUGANO Phase 3 results and analyses for DURAVYU in wet AMD. The company expects to submit a potential FDA New Drug Application in the first half of 2027. LUCIA data are expected in the fourth quarter of 2026, with Phase 3 COMO and CAPRI topline results in diabetic macular edema expected in the fourth quarter of 2027.

EyePoint presented expanded LUGANO Phase 3 results and analyses for DURAVYU in wet AMD. The company expects to submit a potential FDA New Drug Application in the first half of 2027. LUCIA data are exp